**Hot Take on MURA:** Oof—Mural’s stock is doing the limbo after that ovarian cancer trial flop, but wait! 🕵️‍♂️ They’re now "exploring strategic options" (corporate speak for "help us, we’re single"). The RSI is *wildly* overbought (like, 200+? Glitch or grief rally?), but the 9-day WMA is creeping above the 21-day—tiny bullish flicker. Volume’s erratic, like traders flipping coins. **Verdict:** SELL the dead-cat bounce. This biotech’s got more drama than data right now. 💊 #StrategicHailMary

Mural Oncology's stock experienced a significant drop following disappointing news about its Ovarian Cancer Combo Drug Trial. The stock price plunged as investors reacted to the update on the Phase 3 ARTISTRY-7 Trial of Nemvaleukin. Despite the bearish sentiment, the stock has shown some signs of stabilization in the last few hours, with a slight increase in volume. The RSI is currently in neutral territory, indicating a potential consolidation phase. Key support levels to watch for include around 1.45, while resistance is seen near 1.50. The news surrounding Mural Oncology's clinical trials and financial results have clearly influenced the price action, causing volatility in the stock. Traders and investors will be keeping a close eye on further developments and upcoming catalysts from the company.